OMER vs. NKTR, VNDA, ASMB, SKYE, IVA, ACET, TELO, VERU, ATOS, and ALIM
Should you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Nektar Therapeutics (NKTR), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Skye Bioscience (SKYE), Inventiva (IVA), Adicet Bio (ACET), Telomir Pharmaceuticals (TELO), Veru (VERU), Atossa Therapeutics (ATOS), and Alimera Sciences (ALIM). These companies are all part of the "pharmaceutical preparations" industry.
Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 10.9% of Omeros shares are owned by company insiders. Comparatively, 3.1% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Omeros is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Omeros received 114 more outperform votes than Nektar Therapeutics when rated by MarketBeat users. Likewise, 71.80% of users gave Omeros an outperform vote while only 70.61% of users gave Nektar Therapeutics an outperform vote.
Nektar Therapeutics has a consensus target price of $3.50, suggesting a potential upside of 165.15%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Omeros.
In the previous week, Nektar Therapeutics had 3 more articles in the media than Omeros. MarketBeat recorded 3 mentions for Nektar Therapeutics and 0 mentions for Omeros. Omeros' average media sentiment score of 0.26 beat Nektar Therapeutics' score of -0.20 indicating that Omeros is being referred to more favorably in the media.
Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -306.31%. Nektar Therapeutics' return on equity of -96.80% beat Omeros' return on equity.
Omeros has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Summary
Omeros and Nektar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Omeros News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
